Three expert clinicians, Dr Marina Garassino, Dr Sanjay Popat and Professor Tony Mok presented and discussed cases that illustrated important aspects of the management of ALK-positive NSCLC …… … read more.
The final analyses of two key trials – Checkmate 227, part 1 and FLAURA should help to position nivolumab + ipilimumab combination treatment and to reinforce osimertinib as… read more.
For the second time this year, LungCancer.Med headed to Barcelona for the Annual European Society for Medical Oncology (ESMO) meeting. Written by Christine Clark
Interview by Esther Drain In this video, Professor Solange Peters (University of Lausanne, CH) gives us her updates from ESMO including quality of research at the meeting, how… read more.
There was a lot of great news from the ESMO Congress 2019 in Barcelona for melanoma patients. Written by Esther Drain.
Developing CAR-T cells that are effective in solid tumours is challenging but experience in Hodgkin Lymphoma could pave the way for CAR-T cells in lung cancer. Bi-specific T-cell… read more.
Tumours use a variety of mechanisms to escape the host immune system and overcoming these to increase response rates and improve quality of life are key goals. Manipulation… read more.
Targeted treatments for mutation-driven non-small cell lung cancer have advanced considerably but many questions remain about how to use these drugs to the best advantage and how to… read more.
Immunotherapy has been hailed as a “game changer” in the treatment of lung cancer. As experience and understanding grows, optimal ways of delivering this type of treatment are… read more.
Immunotherapy now has an established place in treatment of non-small cell lung cancer but many questions remain such as the role of tumour mutational burden as a biomarker… read more.
Many of the 4,000 delegates at IMW in Boston this year, such as Professor Mohamad Mohty (Paris, France) highlighted the spirit of collaboration, with locals Professor Paul Richardson and Professor Noopur Raje discussing their highlights… read more.
In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients, the panel staked out their positions at the International… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
